Paolo Cavazza
No más puestos en curso
Fortuna: 11 M $ al 30/04/2024
Perfil
Paolo Cavazza worked as a Principal at SciClone Pharmaceuticals LLC.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 30/06/2023 | 76 580 898 ( 13.01% ) | 11 M $ | 30/04/2024 |
Antiguos cargos conocidos de Paolo Cavazza.
| Empresas | Cargo | Fin |
|---|---|---|
| SCICLONE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
SciClone Pharmaceuticals LLC
 SciClone Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology SciClone Pharmaceuticals LLC was engaged in the development of therapeutic treatment for oncology, infectious diseases, and cardiovascular disorders. It was also offering ZADAXIN for the treatment of hepatitis B, hepatitis C, certain cancers, and used as immune system enhancer, and DC Bead which is used for the novel treatment of liver cancer. The company was founded in 1990 and was headquartered in San Mateo, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Paolo Cavazza